Artemis Q1 FY27 PAT jumps 45% on revenue growth; Tower IV expansion approved

Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

ARTEMISMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.7%Reaction day

₹303.30

prior close

₹305.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-1.2% vs market

Hospital peers, median of 26sector+0.3%-1.1% vs sector

On the reaction day the stock moved 1.2 pts less than Nifty Microcap 250 and 1.1 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-1.1

15m

-0.9

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.7+0.4-1.2+0.3-1.1

Next day

+5.6+1.7+3.9+0.0+5.6

+2.4+2.1+0.3+0.2+2.2

+4.7+2.1+2.6+1.2+3.5

+4.3+2.1+2.2+1.0+3.3

+3.4+1.9+1.5-0.7+4.1

+4.5+2.4+2.1-2.2+6.7

15d

+7.1+3.0+4.0-1.5+8.6

+9.8+3.7+6.0-2.9+12.7

+7.1+1.6+5.6-9.2+16.4

—————

UpDownMarket · Nifty Microcap 250Sector · Hospital peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q1 FY27 standalone revenue rose 13% YoY to Rs 282 crore; net profit jumped 45% to Rs 31.05 crore. EBITDA margin expanded to about 22%. Board approved Tower IV expansion at Sector-51 Gurugram hospital, adding 200+ beds for pediatric and women's health care, with Rs 160-180 crore investment over 2 years. Auditors gave an unmodified review report.

Likely market impact

Strong earnings growth and capacity expansion signal long-term revenue upside. Investment of Rs 160-180 Cr may pressure near-term margins.